Eisai (TYO:4523) and Biogen plan to begin producing active ingredients for their Alzheimer's drug lecanemab in the US, shifting part of the work from Switzerland, Nikkei Asia Review reported Thursday.
The move came amid concern that US President Donald Trump would impose tariffs on pharmaceutical imports, the report said.
Biogen, which manufactures the drug, is preparing to build an ingredient production line at the North Carolina site, with the aim to begin domestic production within one to two years, the report said.
Eisai described the decision as part of its cost-cutting efforts but acknowledged the change would also help hedge against potential US tariffs, Nikkei reported.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.